Soff GA, Miao Y, Bendheim G, et al. - Among patients with solid tumors with chemotherapy-induced thrombocytopenia (CIT), researchers focused on the impacts of romiplostim vs untreated observation in this phase II randomized trial. For at least 4 weeks, platelets less than 100,000/μL were detected in patients prior to enrollment despite delay or dose reduction of chemotherapy. With a target platelet count of 100,000/μL or more, the participants were treated with weekly titrated romiplostim or were monitored with usual care. Correction of platelet count within 3 weeks was considered as the primary endpoint, and the secondary endpoint was resumption of chemotherapy without recurrent CIT. They found that an effective correction of CIT was brought about by romiplostim treatment, and maintenance permitted resumption of chemotherapy without recurrence of CIT in most patients.